Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Vice President, Controller | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,200 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 3,200 · Balance 3,200 F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.92 · Expires 2036-08-31 | Direct | 14,000 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 14,000 · Balance 14,000 F2: 25% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date.
F2: 25% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 14,000 | $0.00 Strike: $24.92 | $0.00 |
DisclosureSEC source: 0001193125-26-381953 · ownership.xml · derivative · entry 2 Gunning Robert William · CIK 0002148571 · Vice President, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Ordinary Shares · 14,000 shares Expires 2036-08-31 F2 · derivative.exercise_date: 25% of the shares underlying the option will vest on August 10, 2026, the one-year anniversay of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-381953 · ownership.xml · nonDerivative · entry 1 Gunning Robert William · CIK 0002148571 · Vice President, Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, September 10, 2026, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.